Annexon (ANNX) vs Immix Biopharma (IMMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immix Biopharma (IMMX) has outperformed Annexon (ANNX) over the past year, gaining 278.1% versus a gain of 30.6%. Immix Biopharma is the larger company by market cap ($766.9 million vs $761.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | IMMX |
|---|---|---|
| Share price | $4.02 | $9.25 |
| Market cap | $761.16M | $766.85M |
| 1-day change | +0.12% | -2.53% |
| YTD return | -20.12% | +81.45% |
| 1-year return | +30.62% | +278.09% |
| 5-year return | -81.77% | — |
| EPS (TTM) | $-1.13 | $-0.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.18 | $15.10 |
| 52-week low | $2.54 | $2.31 |
| Distance from 52-week high | -44.08% | -38.74% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +284.31% | +162.70% |
| Average volume | 3.11M | 1.65M |
| Shares outstanding | 189.58M | 82.90M |
| Employees | 92 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMX has outperformed ANNX by 247.5 percentage points over the past year.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Immix Biopharma
IMMX stock →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
ANNX vs IMMX FAQ
Which is bigger, Annexon or Immix Biopharma?
Immix Biopharma (IMMX) is larger, with a market capitalization of $766.85M compared with $761.16M for Annexon (ANNX).
Which stock has performed better over the past year, ANNX or IMMX?
IMMX returned +278.09% over the past 12 months, compared with +30.62% for ANNX (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and Immix Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.